Jazz raises 2026 revenue forecast to $4.78 billion to $4.85 billion
Jazz posted an adjusted loss of $3.88 per share, a smaller loss than the $3.93 consensus estimate compiled by Finnhub, and raised its 2026 revenue forecast.
Key takeaways
- Jazz Pharmaceuticals (JAZZ) said on Nov. 2 that third-quarter total revenues rose 10% to $1.24 billion and it raised its 2026 revenue forecast to $4.78 billion to $4.85 billion. Adjusted loss was $3.88 per share, a smaller loss than the $3.93 consensus estimate.
Jazz (JAZZ) said on Nov. 2 that third-quarter total revenues rose 10% from a year earlier to $1.24 billion, and it raised its full-year 2026 revenue forecast.
Shares rose 1.8% in after-hours trading as of 5:17 p.m. ET, from a regular-session close of $214.57.
The company posted an adjusted loss of $3.88 per share for the quarter ended Sept. 30. That was a smaller loss than the $3.93 per share consensus estimate compiled by Finnhub.
Revenue of $1.24 billion was above the $1.23 billion estimate.
The quarter included an acquired in-process research and development charge of $754 million for ABS-1230 (JZP6979), a therapy for KCNT1-related epilepsy that Jazz gained when it closed its Actio Biosciences acquisition in September.
Here's how the company did:
- Adjusted loss per share: $3.88, against earnings of $8.13 a year earlier
- Total revenues: $1.24 billion vs. $1.13 billion a year earlier, with $1.23 billion expected
Xywav net product sales rose 12% from a year earlier to $483 million. Epidiolex sales fell 2% to $295 million, and Zepzelca sales rose 32% to $104 million.
Ziihera, which received U.S. Food and Drug Administration approval on Aug. 25, reported $21 million in net product sales in the quarter.
2026 guidance
Jazz raised its total revenue forecast to $4.78 billion to $4.85 billion, up from the $4.60 billion to $4.75 billion range it gave on Aug. 3.
The company also increased its GAAP selling, general and administrative expense forecast to $1.54 billion to $1.60 billion, from $1.51 billion to $1.56 billion, to include restructuring expenses.
President and chief executive officer Renee Gala said the quarter "reflects sustained execution across the business and gives us confidence to raise our full-year total revenue guidance."
Share repurchase program
In October, the board approved a new share repurchase program with no expiration date. It allows the company to buy back up to $500 million of ordinary shares, excluding brokerage commissions.
The company completed its previous repurchase program, announced in July 2024, with $225 million of buybacks in the third quarter.